,user_input,reference_contexts,reference,persona_name,query_style,query_length,synthesizer_name
0,Can you explain what the trial involving Sym004 in Combination with FOLFIRI is about and what it aims to achieve in patients with metastatic colorectal cancer?,"[""CLINICAL TRIAL PROTOCOL\nTrial Title:\nAn Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy\nShort Title:\nSym004 in Combination with FOLFIRI in Metastatic Colorectal Cancer Patients\nSponsor:\nSymphogen A/S\nSponsor's Medical Expert:\nCoordinating Investigator:\nTrial ID:\nSym004-09\nTrial Phase:\nPhase 1b/2a\nEudraCT number:\n2015-003047-19\nIND Number:\n105953\nProtocol Version/Date:\n4.0 / 22-Feb-2017 (Amendment 3)\nPrevious Protocol Versions/Dates:\n3.0 / 05-Aug-2016 (Amendment 2)\n2.0 / 09-Nov-2015 (Amendment 1)\n1.0 / 26-Aug-2015\nList of Responsible Person/ Contact Listing\nLists of Investigators responsible for conducting the trial, medically qualified physicians responsible for all trial site related medical decisions (if other than the Investigators), Monitors, clinical laboratories and other medical and/or\ntechnical departments and/or institutions involved in the trial are provided as separate documents.""]","The trial titled 'An Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy' aims to evaluate the effectiveness of Sym004 when used alongside FOLFIRI in patients who have metastatic colorectal cancer that has progressed after initial treatment. This trial is sponsored by Symphogen A/S and is in Phase 1b/2a, indicating it is in the early stages of testing the drug combination for safety and efficacy.",Experienced Doctor,POOR_GRAMMAR,LONG,single_hop_specific_query_synthesizer
1,Wut iz the significance of a confedential documnt in a clinical trial protocol?,"['CLINICAL TRIAL PROTOCOL\nGCP Statement: The trial will be conducted in compliance with this Clinical Trial Protocol, ICH E6 GCP (1) and applicable regulations.\nThis confidential document is the property of Symphogen A/S. No unpublished information contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties.']","The confidential document is significant as it is the property of Symphogen A/S and contains unpublished information that cannot be passed on, reproduced, published, or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties, ensuring the integrity and confidentiality of the trial.",Experienced Doctor,MISSPELLED,LONG,single_hop_specific_query_synthesizer
2,What does the approval of the Clinical Trial Protocol by the sponsor indicate?,['Sponsor\nI hereby approve the Clinical Trial Protocol as suitable and appropriate for use.\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S'],The approval of the Clinical Trial Protocol by the sponsor indicates that it is deemed suitable and appropriate for use.,Young Nurse,PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
3,What is the role of the investigational product in the clinical trial according to the signature page?,"[""Signature Page Principal Investigator\nI, the undersigned, am responsible for the conduct of the trial at this site and agree;\n- \uf0b7 To assume responsibility for the proper conduct of the clinical trial at this Investigational Site\n- \uf0b7 Not to implement any changes to the Clinical Trial Protocol without agreement from the Sponsor and prior review and written approval from the Ethics Committee, except where necessary to eliminate an immediate hazard to the patient\n- \uf0b7 That I am aware of, and will comply with 'Good Clinical Practice' (ICH GCP) (CPMP/ICH/135/95) and all applicable regulatory requirements\n- \uf0b7 That all site staff to which I have delegated tasks for this clinical trial, are adequately informed about the investigational product(s) and of their trial-related duties and functions as described in the Clinical Trial Protocol\n________________________________\n____________________\nSignature\nDate of Signature\nName:\nAcademic degree:\nFunction:\nInstitution:""]","The investigational product is crucial as it must be adequately understood by all site staff to whom tasks have been delegated for the clinical trial, as described in the Clinical Trial Protocol.",Young Nurse,MISSPELLED,LONG,single_hop_specific_query_synthesizer